Company PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for PTC Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 09:34:53 2024-05-20 am EDT			5-day change	1st Jan Change
38.36 ^USD	+15.91%		+2.62%	+20.08%

03:14pm	Sector Update: Health Care Stocks Mixed Pre-Bell Monday	MT
03:01pm	Sector Update: Health Care	MT

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Number of employees: 1,022

USD in Million	2022	Weight	2023	Weight	Delta
Small Molecule and Gene Therapeutics 100.0 %	699	100.0 %	938	100.0 %	+34.20%

USD in Million	2022	Weight	2023	Weight	Delta
United States 56.7 %	499	71.3 %	532	56.7 %	+6.64%
Non-United States 43.3 %	200	28.7 %	406	43.3 %	+102.84%

Managers	Title	Age	Since
Matthew Klein CEO	Chief Executive Officer	52	19-09-30
Pierre Gravier DFI	Director of Finance/CFO	39	23-07-12
Ellen Welch CTO	Chief Tech/Sci/R&D Officer	-	-
Neil Almstead CTO	Chief Tech/Sci/R&D Officer	57	99-12-31
Kylie O'Keefe IRC	Investor Relations Contact	-	18-04-30
Hege Sollie-Zetlmayer HRO	Human Resources Officer	-	17-12-31
Marla Weetall PRN	Corporate Officer/Principal	-	02-09-30
Christopher Trotta PRN	Corporate Officer/Principal	-	-
Christine Utter AUD	Comptroller/Controller/Auditor	46	09-12-31
Murad Husain PRN	Corporate Officer/Principal	-	14-01-28

Members of the board	Title	Age	Since
Glenn Steele BRD	Director/Board Member	79	15-06-14
Michael Schmertzler CHM	Chairman	72	01-07-31
David Southwell BRD	Director/Board Member	63	05-11-30
Allan Jacobson FOU	Founder	78	98-03-30
Emma Reeve BRD	Director/Board Member	63	18-12-17
Jerome Zeldis BRD	Director/Board Member	74	12-09-27
Alethia Young BRD	Director/Board Member	45	22-06-08
Matthew Klein CEO	Chief Executive Officer	52	19-09-30
Mary Smith BRD	Director/Board Member	61	21-06-07
Stephanie Okey BRD	Director/Board Member	64	18-12-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	76,696,785	74,841,517 ( 97.58 %)	0	97.58 %

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 12.22 %	9,369,014	12.22 %	239 M $
Wellington Management Co. LLP 11.61 %	8,901,565	11.61 %	227 M $
RTW Investments LP 9.680 %	7,423,970	9.680 %	189 M $
BlackRock Advisors LLC 8.988 %	6,893,447	8.988 %	176 M $
Armistice Capital LLC 8.819 %	6,764,000	8.819 %	172 M $
STATE STREET CORPORATION 5.359 %	4,109,792	5.359 %	105 M $
Camber Capital Management LP 5.215 %	4,000,000	5.215 %	102 M $
Cowen & Co. LLC 4.858 %	3,725,626	4.858 %	95 M $
Janus Henderson Investors US LLC 4.785 %	3,669,816	4.785 %	94 M $
Morgan Stanley Investment Management, Inc. 2.690 %	2,063,041	2.690 %	53 M $

Name	Equities	%	Valuation
CLEARPOINT NEURO, INC. 3.32%	894,578	3.32%	4,750,209 $

PTC Therapeutics, Inc.

500 Warren Corporate Center Drive

07059, Warren

+908 222 7000

http://www.ptcbio.com

Name	Category and Sector
PTC Therapeutics International Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

33.1 USD

Average target price

29.5 USD

Spread / Average Target

-10.86%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PTC THERAPEUTICS, INC.	+20.08%	2.54B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.42%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs